AR and posterior cortical atrophy: We endeavour to provide a thorough account of the mechanisms underlying AR activation in PCa and outline current and upcoming AR inhibitors (ARIs) that target different AR driver domains for the treatment of aggressive PCa with a focus on patients who develop castration-resistant prostate cancer (CRPC).